Comparison of 18F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin's disease

被引:63
作者
Kabickova, Edita
Sumerauer, David
Cumlivska, Eliska
Drahokoupilova, Eva
Nekolna, Michaela
Chanova, Marketa
Hladikova, Marie
Kodet, Roman
Belohlavek, Otakar
机构
[1] Charles Univ Prague, Sch Med 2, Dept Paediat Haematol & Oncol, Prague 15006 5, Czech Republic
[2] Charles Univ Prague, Sch Med 2, Dept Radiol Tech, Prague 15006 5, Czech Republic
[3] Charles Univ Prague, Sch Med 2, Dept Med Informat, Prague 15006 5, Czech Republic
[4] Charles Univ Prague, Sch Med 2, Dept Pathol & Mol Med, Prague 15006 5, Czech Republic
[5] Homolce Hosp, Dept Nucl Med, Prague 15003 5, Czech Republic
关键词
F-18-FDG; PET; children; Hodgkin's disease; staging;
D O I
10.1007/s00259-005-0019-9
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: The aim of this study was to perform a prospective, blinded comparison of F-18-fluorodeoxyglucose positron emission tomography (FDG-PET) and conventional staging methods (CSMs) for initial staging of children and adolescents with Hodgkin's disease (HD). Methods: Over a period of 4 years, 55 children and adolescents with HD (mean age 15.5 years, range 3.9-18.9 years) were prospectively recruited into the study. They underwent 61 FDG-PET studies using a dedicated whole-body PET scanner as a part of their initial staging work-up. PET findings were correlated with the results of CSMs, including computed tomography (CT), ultrasound, bone scanning and bone marrow examination. Discordant findings were resolved by magnetic resonance imaging or clinical follow-up (range 2-47 months). Results: PET correctly changed the staging in 15% of patients (seven upstagings, two downstagings). Only two out of 61 patients (3%) were not accurately staged by PET; in these children, PET missed small lymphoma nodules detected on lung CT. The sensitivity of PET and CSMs for pretreatment staging was 96.5% and 87.5%, respectively; specificity was 100% and 60%, and accuracy, 96.7% and 85.2%, respectively. Upon combination of FDG-PET and lung CT, the diagnostic accuracy reached 100% in our series. Conclusion: Our study showed that whole-body FDG-PET is an efficient and useful method for the initial staging of children with HD. FDG-PET in combination with lung CT should be recommended as a screening method prior to other conventional imaging modalities to plan a rational staging protocol. Large multicentre prospective studies are necessary to verify this conclusion.
引用
收藏
页码:1025 / 1031
页数:7
相关论文
共 27 条
[1]   Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDC-PET) for accurate staging of Hodgkin's disease [J].
Bangerter, M ;
Moog, F ;
Buchmann, I ;
Kotzerke, J ;
Griesshammer, M ;
Hafner, M ;
Elsner, K ;
Frickhofen, N ;
Reske, SN ;
Bergmann, L .
ANNALS OF ONCOLOGY, 1998, 9 (10) :1117-1122
[2]   Breast cancer and other second neoplasms after childhood Hodgkin's disease [J].
Bhatia, S ;
Robison, LL ;
Oberlin, O ;
Greenberg, M ;
Bunin, G ;
FossatiBellani, F ;
Meadows, AT .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (12) :745-751
[3]  
Buchmann I, 2001, CANCER, V91, P889
[4]   Detection of lymphoma in bone marrow by whole-body positron emission tomography [J].
Carr, R ;
Barrington, SF ;
Madan, B ;
O'Doherty, MJ ;
Saunders, CAB ;
van der Walt, J ;
Timothy, AR .
BLOOD, 1998, 91 (09) :3340-3346
[5]   18F-FDG PET in children with lymphomas [J].
Depas, G ;
De Barsy, C ;
Jerusalem, G ;
Hoyoux, C ;
Dresse, MF ;
Fassotte, MF ;
Paquet, N ;
Foidart, J ;
Rigo, P ;
Hustinx, R .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 (01) :31-38
[6]   VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: Results of a prospective clinical trial [J].
Donaldson, SS ;
Hudson, MM ;
Lamborn, KR ;
Link, MP ;
Kun, L ;
Billett, AL ;
Marcus, KC ;
Hurwitz, CA ;
Young, JA ;
Tarbell, NJ ;
Weinstein, HJ .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (14) :3081-3087
[7]   Utility of FDG-PET scanning in lymphoma by WHO classification [J].
Elstrom, R ;
Guan, L ;
Baker, G ;
Nakhoda, K ;
Vergilio, JA ;
Zhuang, H ;
Pitsilos, S ;
Bagg, A ;
Downs, L ;
Mehrotra, A ;
Kim, S ;
Alavi, A ;
Schuster, SJ .
BLOOD, 2003, 101 (10) :3875-3876
[8]  
Hermann S, 2005, NUKLEARMED-NUCL MED, V44, P1
[9]   Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease [J].
Hudson, MM ;
Krasin, M ;
Link, MP ;
Donaldson, SS ;
Billups, C ;
Merchant, TE ;
Kun, L ;
Billet, AL ;
Kaste, S ;
Tarbell, NJ ;
Howard, S ;
Friedmann, AM ;
Hurwitz, CA ;
Young, JA ;
Marcus, KC ;
Rai, S ;
Cowan, T ;
Weinstein, HJ .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (22) :4541-4550
[10]  
Hueltenschmidt B, 2001, CANCER-AM CANCER SOC, V91, P302, DOI 10.1002/1097-0142(20010115)91:2<302::AID-CNCR1002>3.0.CO